Board of Management & Directors

Dr Richard Hopkins BSc (Hons) PhD

Executive Chair


Dr Hopkins is an experienced bio-pharmaceutical executive with over 20 years in leadership roles with public biotechnology companies.

With an established track record in drug development of novel therapies focussed in oncology and medicinal cannabis, corporate strategy and financing business development and intellectual property. 

Dr Hopkins recently served as the Managing Director for Zelira Therapeutics and CEO at PharmAust. Also, a co-founder of Phylogica, where, in addition to the CEO role, he served in variety of positions, including Chief Scientific Officer, and Chief Operating Officer.

Dr Hopkins has managed and overseen strategic alliances and licensing deals with multiple global pharmaceutical partners including J&J, Pfizer, Roche, Genentech, AstraZeneca/Medimmune, generated over $14 million in revenues as well as building and launching strong proprietary pipelines. 

Dr Hopkins is an author on over 30 peer-reviewed publications and is an inventor on 15 patents and patent applications. 

Karinza Phoenix MBA, GAICD

CEO & Managing Director


A pragmatic and commercially driven leader with over 20 years of experience in the pharmaceutical, veterinary and capital markets sectors.

She is experienced in operational and marketing roles at Pfizer, Novartis and Zoetis.

A successful track record of product development, registration & product marketing launches, including commercialisation of numerous market leading blockbuster medicines.

Specialising in M&A, building high performance teams and cultures, corporate development and legal.

Having worked with a wide range of ASX listed companies in the last 7 years executing capital raising and investor relations strategies. She also completed the Pfizer Inc, 1-year internal leadership program in 2012.

Milton Grannatt PhD

Non-Executive Director


30 years in the global pharmaceuticals industry.

Previously Vice President of Global Business Development and Licensing at Novartis, and Non-Executive Director of SymBio Pharmaceuticals Limited.

Advisor to VOX Telehealth, BioHealthonomics Inc and Transparency Life Sciences.

Otto Buttula

Non-Executive Director


Mr Buttula is a prominent investor and has over 30 years executive and director experience across many sectors of business including biotechnology. He brings considerable skills to Myopharm as it moves forward on executing its business plans.

Mr Buttula’s former roles include Managing Director of Lonsdale Securities and Investors Mutual, companies which he founded. He has served on numerous public listed company boards including Investorfirst, now HUB24 (ASX:HUB), and Non-Executive Director at Imugene (ASX IMU). Mr Buttula currently serves as Chairman at Rhythm Biosciences Limited (ASX: RHY), HITIQ Limited (ASX:HIQ) and OncoSil Medical Ltd (ASX:OSL).

Phillip Hains CA, MBA

Chief Financial Officer & Company Secretary


Myopharm outsources its finance and company secretarial requirements to a specialist public practice, 'The CFO Solution'. Mr Phillip Hains brings over 30 years of experience in corporate secretarial, accounting and general management through his firm The CFO Solution, a boutique professional services firm for listed companies. Mr Hains is currently the Company Secretary of several ASX listed companies.